Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
XOMA 
XOMA Corp (XOMA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: XOMA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $69.67
1 Year Target Price $69.67
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 57.06% | Avg. Invested days 44 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 447.37M USD | Price to earnings Ratio - | 1Y Target Price 69.67 |
Price to earnings Ratio - | 1Y Target Price 69.67 | ||
Volume (30-day avg) 4 | Beta 1.02 | 52 Weeks Range 18.35 - 39.92 | Updated Date 10/14/2025 |
52 Weeks Range 18.35 - 39.92 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -21.47% | Operating Margin (TTM) 35.06% |
Management Effectiveness
Return on Assets (TTM) -2.35% | Return on Equity (TTM) -10.03% |
Valuation
Trailing PE - | Forward PE 29.5 | Enterprise Value 508719409 | Price to Sales(TTM) 9.95 |
Enterprise Value 508719409 | Price to Sales(TTM) 9.95 | ||
Enterprise Value to Revenue 39.83 | Enterprise Value to EBITDA 54 | Shares Outstanding 12087719 | Shares Floating 9294972 |
Shares Outstanding 12087719 | Shares Floating 9294972 | ||
Percent Insiders 1.74 | Percent Institutions 68.04 |
Upturn AI SWOT
XOMA Corp
Company Overview
History and Background
XOMA Corporation, founded in 1981, is a biotechnology company focused on developing antibody-based therapeutics. Initially focused on developing products in-house, XOMA shifted to a royalty aggregator model, acquiring rights to future milestones and royalties on partnered programs.
Core Business Areas
- Royalty Aggregation: XOMA acquires economic rights to future potential milestone payments and royalties associated with partnered biopharmaceutical programs. They don't conduct drug discovery or clinical trials themselves.
Leadership and Structure
XOMA is led by a board of directors and an executive management team. Jim Neal is currently the Chief Executive Officer.
Top Products and Market Share
Key Offerings
- Royalties on Partnered Programs: XOMA's revenue comes from royalties and milestone payments from pharmaceutical companies licensing or co-developing drugs that incorporate XOMA's antibody technologies. Market share data is not directly applicable as they are a royalty aggregator and do not sell a direct product. Competitors are other royalty aggregators and investment firms involved in funding pharmaceutical development.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high R&D costs, long development timelines, regulatory hurdles, and high risks. Success hinges on effective partnering and innovative technologies.
Positioning
XOMA occupies a niche as a royalty aggregator, mitigating the risks of traditional drug development by diversifying across multiple partnered programs. Their competitive advantage lies in their ability to identify and acquire valuable royalty streams.
Total Addressable Market (TAM)
The TAM is difficult to quantify precisely, but it correlates to the total value of potential royalties and milestones in the biopharmaceutical industry. XOMA is positioned to capture a fraction of this TAM through its royalty acquisitions.
Upturn SWOT Analysis
Strengths
- Diversified portfolio of royalty streams
- Reduced risk compared to traditional drug development
- Experienced management team
- Potential for significant returns from successful partnered programs
Weaknesses
- Dependence on the success of partnered programs
- Limited control over drug development and commercialization
- Uncertainty in timing and amount of royalty payments
- Competition from other royalty aggregators
Opportunities
- Acquiring additional royalty streams on promising drug candidates
- Expanding partnerships with pharmaceutical companies
- Investing in new technologies or platforms
- Potential for increased royalty revenue as partnered programs progress
Threats
- Failure of partnered programs in clinical trials
- Delays in regulatory approvals
- Changes in market conditions or competitive landscape
- Patent disputes or challenges to intellectual property
Competitors and Market Share
Key Competitors
- DRI
- RCP
- PDCO
Competitive Landscape
XOMA competes with other royalty aggregators and investment firms that seek to acquire royalty streams from pharmaceutical companies. Their competitive advantage lies in their expertise and ability to identify valuable opportunities.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been variable, depending on the acquisition of new royalty streams and the performance of existing partnered programs.
Future Projections: Future growth depends on the success of XOMA's partnered programs and its ability to acquire new royalty streams. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives focus on identifying and acquiring new royalty opportunities and optimizing their existing portfolio.
Summary
XOMA is a biotechnology royalty aggregator, which is a business model that provides lower risk compared to typical pharma companies. XOMA does not manufacture products, so they are reliant on the success of the companies who have the rights. Revenue can be unpredictable so investor confidence fluctuates based on partner progression. They need to acquire more partnerships to drive growth and reduce reliance on existing agreements.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Financial News Sources
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market share data for royalty aggregators is difficult to obtain and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About XOMA Corp
Exchange NASDAQ | Headquaters EmeryVille, CA, United States | ||
IPO Launch date 1989-04-05 | CEO & Director Mr. Owen P. Hughes Jr. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.xoma.com |
Full time employees 13 | Website https://www.xoma.com | ||
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.